Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]-

Request For Quotation
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Suppliers list
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Basic information
Product Name:Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]-
Synonyms:Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]-;NN-390
CAS:2490284-25-6
MF:C17H16F4N2O4S
MW:420.38
EINECS:
Product Categories:
Mol File:2490284-25-6.mol
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Structure
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Chemical Properties
density 1.463±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO: soluble
form A crystalline solid
pka8.83±0.10(Predicted)
Safety Information
MSDS Information
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Usage And Synthesis
UsesNN-390 is a potent and selective HDAC6 inhibitor, with an IC50 of 9.8 nM. NN-390 penetrates the blood-brain barrier (BBB). NN-390 shows study potential in metastatic Group 3 MB (medulloblastoma)[1].
in vivo

NN-390 (male CD-1 mice, 20 mg/kg, IP, single dose) increases plasma stability[1].
NN-390 can improve PAMPA (parallel artificial membrane permeability assay)-BBB (blood-brain barrier) score[1].
Pharmacokinetic Parameters of NN-390 in male male CD-1 mice[1].

CompoundKT-5315a; NN-390
t1/2 (h)1.051.90
Cmax (ng/mL)493750
AUClast (h*ng/mL)15762523
AUClnf (h*ng/mL)15192548
AUC/D (h*ng/mL)79126
Animal Model:CD-1 mice (male, n=3)[1]
Dosage:20 mg/kg
Administration:IP, single dose (Pharmacokinetic Analysis)
Result:Had a half-life of 115 min in human plasma, a 2.8-fold increase in stability.
IC 50HDAC6: 9.8 nM (IC50); HDAC3: >1 μM (IC50); HDAC8: >1 μM (IC50); HDAC11: >1 μM (IC50); HDAC1: >5 μM (IC50); HDAC2: >5 μM (IC50)
References[1] Nawar N, Bukhari S, Adile AA, et al. Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma. J Med Chem. 2022;65(4):3193-3217. DOI:10.1021/acs.jmedchem.1c01585
Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]- Preparation Products And Raw materials
Tag:Benzamide, N-hydroxy-4-[[(1-methylethyl)[(2,3,4,5-tetrafluorophenyl)sulfonyl]amino]methyl]-(2490284-25-6) Related Product Information
Belinostat (PXD101) 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide BML-210 TRICHOSTATIN A Carbamazepine